Esta empresa está capitalizada por Innvierte, iniciativa de inversión de CDTI, E.P.E. This company is capitalized by Innvierte, an investment program of CDTI, E.P.E.
ADRisk Project. A New Non-Genetic Method to Evaluate Alzheimer’s Disease Risk Using Clinical Chemistry Analyzers – 2018 – Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020 – European Commission
Biocross has developed the first non-genetic test designed to identify people at risk of developing AD by using the high-throughput chemistry analyzers present in hospitals and clinical labs.
Immunoturbidimetric test based on a unique method for capturing apolipoproteins present in blood. This patented method avoids the use of capture antibodies, which makes the test very competitive in price.
Furthermore, ApoE4 detection by immunoturbidimetry represents a highly innovative solution that overcomes many of the drawbacks and shortcomings of current techniques of APOE gene analysis and would translate into a fast, accurate and unexpansive way of detecting people at risk of AD within the clinical routine of hospitals and clinical labs. Seal of Excellence (Download pdf)
AD-2step aims at validating a diagnostic test for Alzheimer’s disease (AD) based on several previously identified markers in the blood. This blood-based test will be easily adaptable to medical laboratories with standard analysis platforms, allowing an inexpensive diagnosis. It represents an important business opportunity, and a key scientific breakthrough that would allow for the first time the differential diagnosis of dementia.
The development of strategic partnerships and alliances represents a key challenge for Biocross. The development of strategic partnerships and alliances represents a key challenge for Biocross, and is of the utmost importance given the continuous changes occuring within the field of neurology.
The main objective is to develop a product that enables diagnosis of Alzheimer’s disease from blood samples with a sensitivity and specificity higher than that of any currently available method (>85%).
To develop new experimental and technological approaches to identify candidate compounds for future therapies for nervous system diseases.
The main objective of the project is to develop a prototype of a diagnostic blood test that will enable clinical diagnosis of Alzheimer’s disease with greater accuracy than currently available
The aim of this project is to develop and commercialize new products for the non-invasive diagnosis of Alzheimer’s disease. These will allow diagnosis of this disease at much earlier stages than currently possible, with greater reliability and less disruption to patients
If you have any questions or comments, we will be pleased to attend you
If you have any questions or comments,
we will be pleased to attend you
Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain
+34 983 54 98 96